Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis: A Randomized Clinical Trial

Sarabi, Zhaleh Shariati; Saeidi, M; Khodashahi, Mandana; Rezaie, Ali; Hashemzadeh, Kamila; Khodashahi, Rozita; Heidari, Hadi

doi:10.19082/2700

Cited by 14 publications

(10 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This disease mainly occurs in individuals aged between 20 and 50 years old and its morbidity rate in women is 2-3 times higher than that in men, particularly in older women. The pathological changes of RA result in functional limitations, working disability and poor quality of life (1-4). One of the important therapeutic approaches for RA in western medicinal therapy is to alleviate pain.…”

Section: Introductionmentioning

confidence: 99%

Effect of astragalosides on long non-coding RNA expression profiles in rats with adjuvant-induced arthritis

Jiang

Liu

et al. 2019

Int J Mol Med

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, which occurs in ~1.0% of the general population. Increasing studies have suggested that long non-coding RNAs (lncRNAs) may serve important roles in various biological processes and may be associated with the pathogenesis of different types of disease, including RA. Astragalosides (AST) has been used as a traditional Chinese medicine for the treatment of RA. However, the mechanism underlying its therapeutic effect has remained unclear to date. Thus, there is an urgent need to elucidate the possible mechanism of AST in the treatment of RA from the perspective of lncRNAs. In the present study, the lncRNAs and mRNAs of a vehicle group, animal model group and AST treatment (control) group were determined by Arraystar Rat lncRNA/mRNA microarray. The differentially expressed genes with a fold change >1.5 and P<0.05 were selected and analyzed. Gene Ontology (GO) and pathway analysis was performed using the Database for Annotation, Visualization and Integration Discovery, and the coding-non-coding gene co-expression network was drawn based on the correlation analysis between the differentially expressed lncRNAs and mRNAs. Based on node degree and the correlation between bioinformatics analysis and RA, the critical differentially expressed lncRNAs were selected, analyzed and verified by reverse transcription-quantitative PCR (RT-qPCR) analysis. The results showed that, following AST treatment, up to 75 lncRNAs and 247 mRNAs were found to be differentially expressed among the three groups. GO and pathway analysis manifested that 135 GO terms and 17 pathways were enriched by differentially expressed genes. Four lncRNAs (MRAK012530, MRAK132628, MRAK003448 and XR_006457) were selected as the critical lncRNAs and their trend in expression showed consistency between the RT-qPCR and microarray data. In conclusion, AST had a regulatory effect on differentially expressed lncRNAs during the development of RA, and four lncRNAs could be selected as critical therapeutic targets of AST.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of astragalosides on long non-coding RNA expression profiles in rats with adjuvant-induced arthritis

Jiang

Liu

et al. 2019

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…This persistent inflammatory response is also thought to be an underlying cause for the increased risk of developing CVD in patients with arthritis ( 1 , 2 ). In this context, statins protect from CVD and recent studies suggest that they also reduce disease activity in patients with rheumatoid arthritis ( 4 – 11 ). It is evident that the pleiotropic actions of statins cannot be uniquely ascribed to inhibition of HMGCA reductase activity.…”

Section: Discussionmentioning

confidence: 99%

“…These drugs are now widely used in the treatment of CVD as a result of the above effects and because of their limited adverse effects, and in 2005, their sales in the United States was estimated to be $19.7 billion ( 3 ). Recent evidence suggests that statins may also be useful in treating a number of inflammatory diseases, including rheumatoid arthritis, where atorvastatin ( 4 – 6 ), pravastatin ( 7 ), and simvastatin ( 8 – 11 ) are suggested to exert joint protective actions. It is now apparent that the protective actions of statins, at least in part, are independent of their ability to regulate HMGCA reductase activity ( 12 ); therefore, during the last few years, there has been significant interest in identifying the mechanisms that are responsible for these beneficial actions.…”

mentioning

confidence: 99%

13‐Series resolvins mediate the leukocyte‐platelet actions of atorvastatin and pravastatin in inflammatory arthritis

et al. 2017

View full text Add to dashboard Cite

Rheumatoid arthritis is an inflammatory condition characterized by overzealous inflammation that leads to joint damage and is associated with an increased incidence of cardiovascular disease. Statins are frontline therapeutics for patients with cardiovascular disease and exert beneficial actions in rheumatoid arthritis. The mechanism that mediates the beneficial actions of statins in rheumatoid arthritis remains of interest. In the present study, we found that the administration of 2 clinically relevant statins—atorvastatin (0.2 mg/kg) or pravastatin (0.2 mg/kg)—to mice during inflammatory arthritis up-regulated systemic and tissue amounts of a novel family of proresolving mediators, termed 13-series resolvins (RvTs), and significantly reduced joint disease. Of note, administration of simvastatin (0.2 mg/kg) did not significantly up-regulate RvTs or reduce joint inflammation. We also found that atorvastatin and pravastatin each reduced systemic leukocyte activation, including platelet-monocyte aggregates (∼25–60%). These statins decreased neutrophil trafficking to the joint as well as joint monocyte and macrophage numbers. Atorvastatin and pravastatin produced significant reductions (∼30–50%) in expression of CD11b and major histocompatibility complex class II on both monocytes and monocyte-derived macrophages in joints. Administration of an inhibitor to cyclooxygenase-2, the initiating enzyme in the RvT pathway, reversed the protective actions of these statins on both joint and systemic inflammation. Together, these findings provide evidence for the role of RvTs in mediating the protective actions of atorvastatin and pravastatin in reducing local and vascular inflammation, and suggest that RvTs may be useful in measuring the anti-inflammatory actions of statins.—Walker, M. E., Souza, P. R., Colas, R. A., Dalli, J. 13-Series resolvins mediate the leukocyte-platelet actions of atorvastatin and pravastatin in inflammatory arthritis.

show abstract

“…Worldwide, 6% of men and 21% of women between 50 and 84 years of age suffer from osteoporosis. Osteoporosis is thus one of the four most common health problems, along with cardiovascular disease, stroke, and cancer 1 2 . The mortality associated with a hip fracture within the first year following occurrence is 8–36% 3 4 .…”

Section: Introductionmentioning

confidence: 99%

Discrepancies Between Osteoporotic Fracture Evaluations in Men Based on German (DVO) Osteoporosis Guidelines or the FRAX Score

Witzel

Giessel

Heppner

et al. 2022

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Introduction: Established scores estimate 10-year fracture risk in osteoporosis to assist with treatment recommendations. This study compares and contrasts the risk probabilities of major osteoporotic and hip fractures calculated by the FRAX tool with those of the DVO score, established in German-speaking countries. Material and methods: This seven-year retrospective study analyzes data of 125 male patients (mean age: 59.2±10.7 years) evaluated for osteoporosis. For the DVO score, the therapy threshold of >30% for vertebral and hip fractures suggested by DVO guidelines was implemented. We calculated fracture risks based on FRAX scores with aBMD and applied a common therapy threshold of ≥3% for hip fracture and subsequently determined the “DVO-equivalent risk level” for FRAX-based assessment that would identify as many male patients as identified by the DVO score. Results: Based on DVO score, 60.0% of patients had a 10-year risk of hip and vertebral fractures >30%. The recommendations for individuals based on FRAX scores for hip fracture with aBMD with risk ≥ 3% overlapped with those based on DVO score in 40.8% of patients. Patients identified for treatment only by DVO score presented a higher percentage of spine fractures (65% vs. 41%). The thresholds for this “DVO-equivalent risk level” for ‘FRAX with aBMD’ would be ≥ 6.9% for MOF and ≥ 2.1% for HF. This study demonstrates that the DVO score was more sensitive than the FRAX score for patients with spinal fractures. We suggest considering the appropriate score and therapy threshold carefully in the daily care of male patients.

show abstract

Evaluation of the Anti-inflammatory Effects of Atorvastatin on Patients with Rheumatoid Arthritis: A Randomized Clinical Trial

Cited by 14 publications

References 15 publications

Effect of astragalosides on long non-coding RNA expression profiles in rats with adjuvant-induced arthritis

Effect of astragalosides on long non-coding RNA expression profiles in rats with adjuvant-induced arthritis

13‐Series resolvins mediate the leukocyte‐platelet actions of atorvastatin and pravastatin in inflammatory arthritis

Discrepancies Between Osteoporotic Fracture Evaluations in Men Based on German (DVO) Osteoporosis Guidelines or the FRAX Score

Contact Info

Product

Resources

About